Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ryberg, M.
Right arrow Articles by Dombernowsky, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryberg, M.
Right arrow Articles by Dombernowsky, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:81-87, 2001
© 2001 European Society for Medical Oncology

research-article

Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy

M. Ryberg, D. Nielsen, K. Østerlind, T. Skovsgaard and P. Dombernowsky

Department of Oncology, Herlev Hospital, University of Copenhagen Denmark

M Ryberg MD Department of Oncology Herlev Hospital, University of Copenhagen Herlev Ringvej DK-2730 Herlev Denmark E-mail mananneryberg{at}dadlnetdk

BACKGROUND: Analysis of prognostic factors in patients with metastatic breast cancer treated with epirubicin-based chemo-therapy

PATIENTS AND METHODS: Data from 469 patients treated with epirubicin-based chemotherapy for metastatic breast cancer were used Prognostic factors were identified (Cox multivanate analysis). A prognostic index was compiled and risk groups were established accordingly. The applicability of the index was investigated in a series of 116 patients

RESULTS: The prognostic factors identified were, liver, pleural, soft tissue, lung and bone metastases, performance status >2, advancing age, abnormal elevation of serum lactate dehydrogenase and negative/unknown oestrogen receptor status. Four risk groups were established good, intermediate 1, intermediate II and poor The median and five-year survivals in percentage were, good 34 months (26%), intermediate I: 19 months (6%), intermediate II. 12 months (0%); poor. 7 months (1%) The corresponding values in the applicability group were 32 months (23%), 28 months (22%), 18 months (5%); and 6 months (0%)

CONCLUSIONS: It is more the number and impact on the organs involved, that predict the patients survival The construction of a prognostic index could be helpful in assessing the outlook for patients, especially the quite dramatic difference in long-term survival between the good and poor risk patients.

epirubicin, metastatic breast cancer, prognostic factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
E. Chamorey, J. Barriere, J. M. Ferrero, and R. Largillier
Reply to Adjuvant chemotherapy and prognosis in patients with breast cancer
Ann. Onc., January 1, 2009; 20(1): 193 - 194.
[Full Text] [PDF]

Home page
 Ann OncolHome page
R. Largillier, J.-M. Ferrero, J. Doyen, J. Barriere, M. Namer, V. Mari, A. Courdi, J. M. Hannoun-Levi, F. Ettore, I. Birtwisle-Peyrottes, et al.
Prognostic factors in 1038 women with metastatic breast cancer
Ann. Onc., December 1, 2008; 19(12): 2012 - 2019.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Ryberg, D. Nielsen, G. Cortese, G. Nielsen, T. Skovsgaard, and P. K. Andersen
New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients
J Natl Cancer Inst, August 6, 2008; 100(15): 1058 - 1067.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter, and A. L. Harris
Lactate Dehydrogenase 5 Expression in Operable Colorectal Cancer: Strong Association With Survival and Activated Vascular Endothelial Growth Factor Pathway--A Report of the Tumour Angiogenesis Research Group
J. Clin. Oncol., September 10, 2006; 24(26): 4301 - 4308.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. Fiegl, H. Denz, I. H. Kunkler, C. Tang, A. Y. Lin, A. C. Voogd, K. van Gestel, M. F. Ernst, M. Cristofanilli, L. W.M.M. Terstappen, et al.
Circulating Epithelial Cells in Breast Cancer
N. Engl. J. Med., December 2, 2004; 351(23): 2452 - 2454.
[Full Text] [PDF]

Home page
 Ann OncolHome page
V. R. Rozados, A. M. Sanchez, S. I. Gervasoni, H. H. Berra, P. Matar, and O. Graciela Scharovsky
Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity
Ann. Onc., October 1, 2004; 15(10): 1543 - 1550.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.